AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 6 - (NewsRx.com & NewsRx.net) --
Researchers have developed a DNA vaccine against herpes simplex virus type 1 (HSV-1) that decreases severity of disease in the eye in mice infected with HSV-1 by the corneal route.
Immunization with the construct also decreases the magnitude of the acute infection of the trigeminal ganglia, the nerve where HSV-1 can establish a latent or non-productive state. Despite the decrease in the acute infection of the trigeminal nerve, latency was still established in immunized mice, reported Tricia Frye and her professors at Wright State University, Dayton, Ohio, and The Immune Response Corp., Carlsbad, California.
HSV-1 is the leading cause of blindness by an infectious agent. Control of the disease within the eye could ameliorate the destruction caused by infection.
Immunized mice were infected with HSV-1 by the corneal route and monitored for 21 days following infection. The mice were scored based on the degree of disease symptoms displayed: weeping eyes, edema, visible lesions. At days 2, 4, 7, 9, and 11 post-infection, the trigeminal ...